Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Kalaris Therapeutics (NASDAQ:KLRS) from a hold rating to a sell rating in a research note released on Saturday.

A number of other brokerages also recently commented on KLRS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Chardan Capital started coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kalaris Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Stock Up 1.4%

Shares of Kalaris Therapeutics stock opened at $9.82 on Friday. The firm’s 50 day moving average is $9.36 and its two-hundred day moving average is $6.94. The firm has a market capitalization of $183.63 million, a P/E ratio of -2.60 and a beta of -0.13. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $12.90.

Insider Transactions at Kalaris Therapeutics

In other news, Director Srinivas Akkaraju purchased 479,847 shares of the stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $10.42 per share, with a total value of $5,000,005.74. Following the completion of the transaction, the director owned 1,979,847 shares in the company, valued at approximately $20,630,005.74. The trade was a 31.99% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 74.99% of the company’s stock.

Institutional Investors Weigh In On Kalaris Therapeutics

Institutional investors have recently bought and sold shares of the business. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kalaris Therapeutics in the 4th quarter valued at $34,000. Barclays PLC purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter worth about $51,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the third quarter valued at about $58,000. XTX Topco Ltd purchased a new stake in shares of Kalaris Therapeutics during the 2nd quarter valued at about $65,000. Finally, Keel Point LLC purchased a new stake in shares of Kalaris Therapeutics during the 4th quarter valued at about $86,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.